Aclaris Therapeutics: Q4 Earnings Insights
$ACRS
Biotechnology: Pharmaceutical Preparations
Health Care
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q4 earnings results on Tuesday, February 27, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Aclaris Therapeutics beat estimated earnings by 12.0%, reporting an EPS of $-0.3 versus an estimate of $-0.34.
Revenue was up $9.82 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.07 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Aclaris Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.48 | -0.45 | -0.44 | -0.45 |
| EPS Actual | -0.41 | -0.42 | -0.42 | -0.41 |
| Revenue Estimate | 1.57M | 1.90M | 1.75M | 1.99M |
| Revenue Actual | 9.28M | 1.87M | 2.53M | 7.75M |
To track all earnings releases for Aclaris Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.